Brind.

Arrowhead Pharmaceuticals filed both NDA and MAA for plozasiran treatment on August 8, 2025.

1 report, 1 independent Updated Aug 8

AI-generated analysis. Brind wrote this summary from the reports listed below. It can be wrong. Each section says how much you can rely on it, and the sources are linked so you can check.

What happened

Some supportReported by 1 outlet

Who's involved

What this event is mainly about

FDA Arrowhead Pharmaceuticals

Keep exploring

The entities involved

FDA
- Generic medicine services are seeking approval for launch from the FDA.Mon 17:49
- A company is seeking FDA feedback on its NEO212 program, with a meeting scheduled at the FDA's White Oak campus.Mon 14:56
Arrowhead Pharmaceuticals
biopharmaceutical company

Nothing else this week.

Related events

BridgeBio plans to submit MAA and NDA for infigratinib review to the FDA.Jun 28

Coverage

Newest first; wire copies grouped

Aug 8Zacks Small Cap ResearchARWR: Countdown to Nov. 18, 2025 PDUFA for Plozasiran for FCS… By David Bautz, PhD NASDAQ:ARWR READ THE FULL ARWR RESEARCH REPORT Business Update Countdown Begins to November 18, 2025 PDUFA for Ploza